Abstract: The invention provides a transgenic mouse which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.
Type:
Grant
Filed:
September 23, 1999
Date of Patent:
March 27, 2001
Assignee:
Aventis Behring GmbH
Inventors:
Gerhard Dickneite, Hubert Metzner, Gerd Zettlmeissl, Ulrich Grundmann, Richard Lathe, Austin Smith, Meng Li
Abstract: Novel SPOIL-1 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length SPOIL-1 proteins, the invention further provides isolated SPOIL-1 fusion proteins, antigenic peptides and anti-SPOIL-1 antibodies. The invention also provides SPOIL-1 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a SPOIL-1 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
Abstract: The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.
Type:
Grant
Filed:
August 10, 1998
Date of Patent:
January 16, 2001
Assignee:
The Regents of the University of California
Inventors:
H. Kirk Hammond, Frank J. Giordano, Wolfgang H. Dillmann
Abstract: The subject invention pertains to recombinant entomopox vectors which are useful for the delivery and stable expression of heterologous DNA in vertebrate cells. Specifically exemplified is a recombinant EPV from amsacta moorei (AmEPV). Because of the capacity of the EPV to incorporate foreign or heterologous DNA sequences, the vectors of the subject invention can be used to deliver DNA inserts that are larger than 10 kb in size. Accordingly, one aspect of the present invention concerns use of the recombinant vectors for delivery and expression of biological useful proteins in gene therapy protocols.
Abstract: The invention relates to a method for making monoclonal antibodies having pre-defined specificity for an epitope characteristic of or unique to a single form of a polymorphic protein. The method includes constructing a first transgenic animal to express a first form of a polymorphic protein encoded by a first allele of a gene encoding the protein; constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein; and immunizing the first transgenic animal with cells from the second transgenic animal expressing the second form of the polymorphic protein to induce an immune response in the first transgenic animal yielding an antibody specific for an epitope peculiar to the second form of the polymorphic protein. The invention further includes hybridoma cells secreting a monoclonal antibody specific for the second form of the protein.